Diagnostic value of fecal tumor M2-pyruvate kinase for CRC screening: A systematic review and meta-analysis

International Journal of Cancer

Volumn 131, Issue 8, 2012, Pages 1837-1845

  Li, Rui ^a   Liu, Jianjun ^a   Xue, Huiping ^b   Huang, Gang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

colorectal cancer; feces; meta analysis; pyruvate kinase; tumor M2 pyruvate kinase

Indexed keywords

GUAIAC; PYRUVATE KINASE; TUMOR M2 PYRUVATE KINASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER SCREENING; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FECES ANALYSIS; GUAIAC FECAL OCCULT BLOOD TEST; HUMAN; IMMUNOLOGICAL FECAL OCCULT BLOOD TEST; INTERMETHOD COMPARISON; OCCULT BLOOD TEST; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

COLORECTAL NEOPLASMS; DIAGNOSTIC TESTS, ROUTINE; EARLY DETECTION OF CANCER; HUMANS; OCCULT BLOOD; PYRUVATE KINASE; REVIEW LITERATURE AS TOPIC; ROC CURVE;

EID: 84865334837     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27442     Document Type: Article

References (50)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Wilson JM, Jungner YG,. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam 1968; 65: 281-393.
3. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM,. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA-J Am Med Assoc 2000; 284: 1954-61.
4. Ekelund G, Manjer J, Zackrisson S,. Population-based screening for colorectal cancer with faecal occult blood testâ€"do we really have enough evidence? Int J Colorectal Dis 2010; 25: 1269-75.
5. Walsh JM, Terdiman JP,. Colorectal cancer screening: scientific review. JAMA 2003; 289: 1288-96. (Pubitemid 37432910)
6. Pignone M, Campbell MK, Carr C, Phillips C,. Meta-analysis of dietary restriction during fecal occult blood testing. Eff Clin Pract 2001; 4: 150-6.
7. Dancourt V, Lejeune C, Lepage C, Gailliard MC, Meny B, Faivre J,. Immunochemical faecal occult blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms. Eur J Cancer 2008; 44: 2254-8.
8. Duffy MJ, van Rossum LG, van Turenhout ST, Malminiemi O, Sturgeon C, Lamerz R, Nicolini A, Haglund C, Holubec L, Fraser CG, Halloran SP,. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Int J Cancer 2011; 128: 3-11.
9. Hardt PD, Toepler M, Ngoumou B, Rupp J, Kloer HU,. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Res 2003; 23: 851-3. (Pubitemid 36750884)
10. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E,. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 2005; 15: 300-08. (Pubitemid 41058775)
11. Moses LE, Shapiro D, Littenberg B,. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 1993; 12: 1293-316. (Pubitemid 23230833)
12. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J,. Assessing heterogeneity in meta-analysis: Q statistic or I-2 index? Psychol Methods 2006; 11: 193-206. (Pubitemid 44001277)
13. Egger M, Davey Smith G, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34. (Pubitemid 27387172)
14. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH,. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005; 58: 982-90. (Pubitemid 41316441)
15. Rutter CM, Gatsonis CA,. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med 2001; 20: 2865-84. (Pubitemid 32923212)
16. Petra Macaskill CG, Deeks J, Harbord R, Takwoingi Y,. Chapter 10: Analysing and Presenting Results. In:, Deeks JJ BP, Gatsonis C,. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0.ed. The Cochrane Collaboration; 2010: 26-27.
17. Hardt PD, Mazurek S, Toepler M, Schlierbach P, Bretzel RG, Eigenbrodt E, Kloer HU,. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer 2004; 91: 980-4. (Pubitemid 39273794)
18. Naumann M, Schaum B, Oremek GM, Hanisch E, Rosch W, Mossner J, Caspary WF, Stein J,. Faecal pyruvate kinase type M2â€"a valid screening parameter for colorectal cancer? Preliminary results from a multicenter comparative study. Dtsch Med Wochenschr 2004; 129: 1806-7.
19. Vogel T, Driemel C, Hauser A, Hansmann A, Lange S, Jonas M, Moslein G,. Comparison of different stool tests for the detection of cancer of the colon. Dtsch Med Wochenschr 2005; 130: 872-7. (Pubitemid 40545296)
20. Shastri YM, Naumann M, Oremek GM, Hanisch E, Rosch W, Mossner J, Caspary WF, Stein JM,. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal ecoplasia. Int J Cancer 2006; 119: 2651-56. (Pubitemid 44691321)
21. Tonus C, Neupert G, Sellinger M,. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK. World J Gastroenterol 2006; 12: 7007-11. (Pubitemid 44834892)
22. Mulder SA, Van Leerdam ME, Van Vuuren AJ, Francke J, Van Toorenenbergen AW, Kuipers EJ, Ouwendijk RJT,. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. Eur J Gastroenterol Hepatol 2007; 19: 878-82. (Pubitemid 47415147)
23. Koss K, Maxton D, Jankowski JA,. Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention. Colorectal Dis 2008; 10: 244-8. (Pubitemid 351284676)
24. Shastri YM, Loitsch S, Hoepffner N, Povse N, Hanisch E, Rösch W, Mössner J, Stein JM,. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study. Am J Gastroenterol 2008; 103: 1496-504. (Pubitemid 351813913)
25. Cai GF, Wang JP, Huang YH, Lan P, Song XM,. Evaluation of fecal tumor M2 pyruvate kinase combined with fecal occult blood test as a detecting tool for colorectal cancer. J Sun Yat-sen Univ (Med Sci) 2006: 350-3.
26. Zhang Y, Gu WQ, Zhang L, Ran ZH,. Significance of fecal tumor M2 pyruvate kinase for detection of gastrointestinal cancers. Chin J Gastroenterol 2007; 12: 465-68.
27. Starostina MA, Afanas'eva ZA, Zinkevich OD, Safina NA,. Informativeness of screening methods of patients with colorectal cancer. Kazanskii Meditsinskii Zhurnal 2011; 97: 20-21.
28. Begg CB,. Biases in the assessment of diagnostic tests. Stat Med 1987; 6: 411-23. (Pubitemid 17110905)
29. Kumar Y, Tapuria N, Kirmani N, Davidson BR,. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker. Eur J Gastroenterol Hepatol 2007; 19: 265-76.
30. Schneider J, Morr H, Velcovsky HG, Weisse G, Eigenbrodt E,. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases. Cancer Detect Prev 2000; 24: 531-5. (Pubitemid 32099839)
31. Weinberger R, Appel B, Stein A, Metz Y, Neheman A, Barak M,. The pyruvate kinase isoenzyme M2 (Tu M2-PK) as a tumour marker for renal cell carcinoma. Eur J Cancer Care (Engl) 2007; 16: 333-7.
32. Haug U, Brenner H,. New faecal tests for colorectal cancer screening: is tumour pyruvate kinase M2 one of the options?â€"Reply. Br J Cancer 2007; 97: 1597-97.
33. Shastri YM, Stein JM,. Faecal tumour pyruvate kinase M2: not a good marker for the detection of colorectal adenomas. Br J Cancer 2008; 99: 1366; author reply 67.
34. Ewald N, Schaller M, Bayer M, Akinci A, Bretzel RG, Kloer HU, Hardt PD,. Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer. Anticancer Res 2007; 27: 1949-52. (Pubitemid 46954705)
35. Brawley OW, Kramer BS,. Cancer screening in theory and in practice. J Clin Oncol 2005; 23: 293-300. (Pubitemid 46206880)
36. Huang CS, Lal SK, Farraye FA,. Colorectal cancer screening in average risk individuals. Cancer Causes Control 2005; 16: 171-88. (Pubitemid 40685059)
37. Feinberg EJ, Steinberg WM, Banks BL, Henry JP,. How long to abstain from eating red meat before fecal occult blood tests. Ann Intern Med 1990; 113: 403-4. (Pubitemid 20262828)
38. Lynch NM, McHutchison JG, Young GP, Deacon M, St John DJ, Barraclough D,. Gastrointestinal blood loss from a new buffered aspirin (Ostoprin): measurement by radiochromium and Hemoquant techniques. Aust N Z J Med 1989; 19: 89-96. (Pubitemid 19216764)
39. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L,. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008; 103: 1541-9. (Pubitemid 351813919)
40. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R,. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149: 638-58.
41. Malila N, Oivanen T, Malminiemi O, Hakama M,. Test, episode, and programme sensitivities of screening for colorectal cancer as a public health policy in Finland: experimental design. BMJ 2008; 337: 1341-1344.
42. Towler B, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C,. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. BMJ 1998; 317: 559-65. (Pubitemid 28395924)
43. Rosman AS, Korsten MA,. Effect of verification bias on the sensitivity of fecal occult blood testing: a meta-analysis. J Gen Intern Med 2010; 25: 1211-21.
44. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, Dash C, Giardiello FM, Glick S, Johnson D, Johnson CD, Levin TR, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008; 134: 1570-95. (Pubitemid 351615355)
45. Haug U, Hundt S, Brenner H,. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study. Br J Cancer 2008; 99: 133-5. (Pubitemid 351920225)
46. Joshi S, Lewis SJ, Creanor S, Ayling RM,. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem 2010; 47: 259-63.
47. Tonus C, Neupert G, Witzel K,. The faecal tumour M2-PK screening test for invasive & pre-invasive colorectal cancer: estimated specificity & results as a function of age for a study population of 4854 volunteers. Nowotwory 2009; 59: 75-81.
48. Rutjes AW, Reitsma JB, Vandenbroucke JP, Glas AS, Bossuyt PM,. Case-control and two-gate designs in diagnostic accuracy studies. Clin Chem 2005; 51: 1335-41. (Pubitemid 41060863)
49. Whiting P, Rutjes AW, Reitsma JB, Glas AS, Bossuyt PM, Kleijnen J,. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med 2004; 140: 189-202. (Pubitemid 38155650)
50. Haug U, Wente MN, Seiler CM, Rothenbacher D, Büchler MW, Brenner H,. Tumor M2 pyruvate kinase as a stool marker for colorectal cancer: stability at room temperature and implications for application in the screening setting [15]. Clin Chem 2006; 52: 782-84.